Mankind Pharma has signed a definitive agreement to acquire a 70% stake in Belgium-based Armed Cell Therapeutics B.V. (ACTx) for €48 million, or approximately ₹511 crore. Announced on October 15, 2026, the transaction marks the Indian pharmaceutical company’s entry into next-generation chimeric antigen receptor T-cell (CAR-T) therapies, an advanced form of cancer treatment that uses engineered immune cells. The acquisition will be carried out through Mankind Pharma (Netherlands) B.V., its wholly owned subsidiary, and forms part of the company’s strategy to build a global, innovation-led pharmaceutical business.
ACTx is developing experimental CAR-T treatments with lead programmes targeting non-Hodgkin lymphoma and small cell lung cancer. Its research includes approaches designed to make engineered immune cells more persistent, improve their ability to attack cancer and potentially generate CAR-T cells directly inside a patient’s body. However, the company’s two lead programmes are preparing for first-in-human studies, which have not yet started. The deal gives Mankind access to a research platform and experienced biotechnology leadership, but any commercial opportunity will depend on clinical evidence, regulatory approvals and successful development.
Key Takeaways
- Acquisition value: Mankind Pharma will invest €48 million, approximately ₹511 crore, for a 70% stake in ACTx.
- New therapeutic area: The deal marks Mankind’s entry into next-generation CAR-T cancer therapy research.
- Lead programmes: ACTx is developing treatments targeting non-Hodgkin lymphoma and small cell lung cancer.
- Experimental technology: Its research includes armed CAR-T cells and in vivo CAR-T generation.
- Early development stage: ACTx’s two lead programmes are preparing for first-in-human studies; human trials have not yet started.
- Experienced founders: The company was founded by biotechnology and drug-development professionals, including former Johnson & Johnson executive Paul Stoffels.
- Long-term opportunity: The acquisition could diversify Mankind’s portfolio, but clinical, regulatory and commercial risks remain significant.
What Is the Mankind Pharma–ACTx Deal?
Mankind Pharma announced the acquisition on October 15, 2026, through a regulatory filing and a company press release. Under the agreement, its Netherlands subsidiary will invest €48 million in ACTx to acquire a majority stake of 70%.
To facilitate the transaction, Mankind Pharma’s board approved an additional investment of up to €45 million in Mankind Pharma (Netherlands) B.V. This raises the subsidiary’s aggregate investment limit to €50 million, including an earlier approved limit of €5 million. The subsidiary will use the funds to make the €48 million investment in ACTx in instalments.
| Deal detail | Information |
|---|---|
| Acquirer | Mankind Pharma |
| Target company | Armed Cell Therapeutics B.V. (ACTx) |
| Target’s incorporation | Belgium |
| Stake to be acquired | 70% |
| Investment amount | €48 million |
| Approximate rupee value | ₹511 crore |
| Acquisition vehicle | Mankind Pharma (Netherlands) B.V. |
| Primary business | Next-generation CAR-T cancer therapy development |
| Lead target indications | Non-Hodgkin lymphoma and small cell lung cancer |
The acquisition is part of Mankind’s long-term plan to expand beyond its established pharmaceutical formulations and consumer healthcare businesses. Instead of relying exclusively on established medicines, the company is seeking access to research platforms that could generate differentiated therapies in complex disease areas.
The transaction is subject to the applicable requirements in the definitive agreement and relevant host-country laws. The company has not disclosed a fixed completion date in the announcement.
What Is CAR-T Cell Therapy?
CAR-T stands for chimeric antigen receptor T-cell therapy. It is a form of immunotherapy that modifies T cells, a type of immune cell, so they can recognise and attack cancer cells.
In conventional CAR-T treatment, T cells are collected from a patient and modified in a specialised laboratory to express a receptor that recognises a target associated with cancer. The engineered cells are expanded and then infused back into the patient, where they can seek out and attack the targeted cells.
CAR-T therapy has changed treatment options for certain blood cancers, particularly in patients whose disease has returned or has not responded adequately to earlier treatments. However, it is complex to manufacture and administer, can be expensive and carries potentially serious risks that require specialist medical monitoring.
The technology also faces challenges in solid tumours. Cancer cells can suppress immune activity, create hostile environments for T cells and change the targets they express. These factors can limit the effectiveness and durability of treatment.
ACTx is working on next-generation approaches intended to address some of these limitations.
What Makes ACTx’s Next-Generation CAR-T Approach Different?
1. Armed CAR-T cells
ACTx is developing what it calls armed CAR-T therapies. In this approach, engineered T cells carry additional biological payloads intended to strengthen or sustain their anti-tumour activity.
The aim is to help the cells remain functional for longer and operate more effectively in challenging tumour environments. This is relevant because conventional CAR-T cells can become exhausted, lose persistence or fail to eliminate all cancer cells.
The company is also exploring strategies that target more than one cancer antigen. Cancer cells can sometimes evade a treatment by reducing or losing the specific target that the therapy recognises. Multi-targeting approaches are designed to make this form of resistance more difficult.
These are research objectives, not established clinical outcomes for ACTx’s programmes. Their safety and effectiveness must be demonstrated through appropriate studies.
2. In vivo CAR-T generation
ACTx also plans to pursue in vivo CAR-T cell generation. In conventional treatment, immune cells are modified outside the body before being returned to the patient. An in vivo approach aims to engineer the patient’s immune cells directly inside the body.
If successfully developed, this method could potentially simplify some manufacturing and logistical steps associated with conventional CAR-T treatment. It might also improve scalability and broaden access to the technology.
However, the approach introduces difficult technical challenges. Researchers must deliver the necessary genetic instructions to the intended cells, avoid unintended effects, control immune responses and demonstrate that the treatment is safe and effective.
In vivo CAR-T remains an active area of research. Potential benefits such as lower costs, simpler manufacturing or wider patient access should not be treated as guaranteed outcomes.
Which Cancers Is ACTx Targeting?
ACTx’s two lead programmes focus on non-Hodgkin lymphoma and small cell lung cancer.
Non-Hodgkin lymphoma
Non-Hodgkin lymphoma is a group of cancers that originate in lymphocytes, a type of white blood cell. The disease includes multiple subtypes with different clinical characteristics and treatment options.
CAR-T therapies are already used for certain forms of blood cancer, including some lymphomas. However, some patients relapse after treatment, creating demand for approaches that could produce more durable responses.
ACTx is developing a next-generation CAR-T programme intended to address limitations associated with current treatment approaches. Its candidate remains experimental, and it has not yet entered human trials.
Small cell lung cancer
Small cell lung cancer is an aggressive form of lung cancer that can progress rapidly. Treatment options depend on the stage of disease and the patient’s clinical circumstances, and the disease can be difficult to control over the long term.
CAR-T development for solid tumours faces additional barriers compared with many blood cancers. Engineered cells must reach tumour sites, recognise appropriate targets and remain active despite the tumour’s local environment.
ACTx’s programme aims to apply its next-generation CAR-T platform to this challenge. The scientific rationale is promising enough to motivate research, but clinical studies will be needed to establish whether the approach benefits patients.
Neither programme should be described as an approved cancer treatment or as a therapy currently available to patients.
Who Founded Armed Cell Therapeutics?
ACTx was founded by a team with experience in biotechnology, clinical research and pharmaceutical development.
Its founders include:
- Dr Paul Stoffels: Chair of ACTx’s board and former chief executive of Galapagos and former chief scientific officer of Johnson & Johnson.
- Dr John Mellors: ACTx’s chief scientific officer, a distinguished professor of medicine at the University of Pittsburgh and a former senior executive responsible for discovery and early development at Galapagos.
- Peter Verhaeghe: A life-sciences lawyer and corporate finance professional who previously chaired argenx.
The leadership team’s experience is relevant to a company attempting to move complex scientific programmes towards clinical development. Drug development requires expertise in target selection, experimental design, manufacturing, regulatory strategy and clinical trial execution.
ACTx’s research and development activities are located in the United States and Europe. The company is headquartered in Belgium, with research and preclinical operations in Pittsburgh and early development activities across several regions.
Access to an experienced team and a specialised research platform is one of the strategic benefits Mankind expects from the acquisition. Nevertheless, experience and scientific promise cannot replace clinical evidence.
Why Is Mankind Pharma Expanding Into Biotechnology?
Mankind Pharma is best known for its domestic pharmaceutical formulations and consumer healthcare businesses. It has an established distribution network and a broad portfolio across acute and chronic therapeutic categories.
The ACTx transaction represents a move towards a more research-led business model. By investing in an external biotechnology company, Mankind can access specialised research capabilities rather than building an entire cell-therapy platform from the ground up.
The strategy could create opportunities to diversify its future product pipeline. If ACTx’s candidates progress through development and eventually receive regulatory approval, Mankind could participate in a new category of advanced therapies.
The company has also previously expanded its presence in specialised healthcare through acquisitions, including Bharat Serums and Vaccines (BSV). The ACTx deal extends that approach into an earlier stage of drug development, where the potential upside can be substantial but uncertainty is also much higher.
The investment does not immediately create revenue from CAR-T medicines. In the near term, the financial impact will principally involve the acquisition outlay and the resources required to support research and development.
What Are the Risks for Mankind Pharma?
The central risk is that ACTx’s programmes are at an early stage. Its lead candidates are preparing for first-in-human studies, so there is not yet human clinical evidence establishing their safety or efficacy.
The main risks include:
- Clinical risk: Experimental treatments may not demonstrate adequate safety or effectiveness in human studies.
- Regulatory risk: Development can require additional studies, and approvals are not guaranteed.
- Manufacturing complexity: Cell therapies can require specialised production, quality controls and logistics.
- Funding requirements: Clinical development can require additional investment beyond the initial acquisition amount.
- Commercial uncertainty: Even a successful therapy must demonstrate a meaningful benefit and compete within its target market.
- Access and affordability: Advanced therapies may be expensive to develop and deliver, making pricing and patient access important considerations.
Investors should therefore distinguish between the €48 million acquisition investment and the potential total cost of developing commercial products over time. The company has not disclosed a complete long-term development budget or a revenue timetable for ACTx’s pipeline.
The Bigger Picture
Mankind Pharma’s acquisition of ACTx reflects a broader effort by Indian pharmaceutical companies to build capabilities in advanced therapies and innovation-led drug development. The deal gives Mankind access to an experimental CAR-T platform, research programmes targeting two difficult cancers and a team with experience in biotechnology and pharmaceutical development.
The commercial outcome remains uncertain because ACTx’s lead programmes have not yet entered human trials. If the research advances successfully, the platform could become a source of differentiated therapies and help Mankind expand internationally. If the candidates fail to demonstrate safety or efficacy, the investment may not produce the expected return. The deal is therefore a strategic entry into an emerging field, not an immediate expansion of approved cancer medicines.
What Happens Next?
The next steps will involve completing the acquisition under the definitive agreement and advancing ACTx’s lead programmes towards first-in-human studies. Progress will depend on preclinical results, manufacturing readiness, trial design and regulatory requirements. Investors should watch for disclosures about completion, research milestones, clinical trial initiation and any additional funding commitments as the programmes develop.
Over the longer term, Mankind’s success in this area will depend on whether ACTx can turn its scientific platform into safe, effective and commercially viable therapies. The proposed use of armed CAR-T cells and in vivo cell generation offers research opportunities, but both approaches must overcome significant technical and clinical challenges. Until human data become available, the acquisition should be viewed as a long-term research investment with substantial uncertainty.
Frequently Asked Questions
1. How much is Mankind Pharma paying for ACTx?
Mankind Pharma will invest €48 million, approximately ₹511 crore, to acquire a 70% stake in Armed Cell Therapeutics through its wholly owned Netherlands subsidiary.
2. What does ACTx do?
ACTx is a Belgium-incorporated biotechnology company developing next-generation CAR-T cancer therapies. Its lead programmes target non-Hodgkin lymphoma and small cell lung cancer.
3. What is CAR-T cell therapy?
CAR-T therapy modifies immune cells so they can recognise and attack cancer cells. It is used for certain cancers, particularly some blood cancers, and requires specialised treatment and monitoring.
4. What is in vivo CAR-T therapy?
In vivo CAR-T generation aims to engineer a patient’s immune cells directly inside the body instead of collecting and modifying the cells outside the body first. The approach remains under development and faces significant safety and delivery challenges.
5. Are ACTx’s cancer therapies approved for patients?
No. ACTx’s two lead programmes are preparing for first-in-human studies, which have not yet started. The candidates remain experimental and have not been established as approved treatments.
6. Why is Mankind Pharma investing in ACTx?
The acquisition gives Mankind access to an advanced research platform and an experienced biotechnology team. It supports the company’s strategy to expand beyond established medicines into innovation-led therapies, although the financial returns remain uncertain.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
